What Altimmune, Inc. told the SEC could break it.

Altimmune has no product revenue and incurred net losses of $88.1M (2025) and $95.1M (2024); it depends on continued equity/debt financing — a Hercules Capital secured loan and multiple ATM programs — and partnering to fund clinical trials.

“We have incurred net losses in most periods since our inception, including a net loss of $88.1 million and $95.1 million for the years ended December 31, 2025 and 2024, respectively.”

The Company's prospects are concentrated in a single lead product candidate, pemvidutide (a glucagon/GLP-1 dual agonist for MASH/AUD/ALD); failure in its trials would be highly material.

“The Company's lead product candidate is pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of MASH, AUD and ALD.”

Future commercialization is exposed to US drug-pricing reform — IRA Medicare Part D mandatory discounts and price negotiation, plus proposed MFN/international-reference models (GLOBE, GUARD) — which could cap reimbursement for its candidates.

“the Inflation Reduction Act of 2022 (“IRA”) includes several provisions that will impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new mandatory discounts from manufacturers under Medicare Part D, allow the U.S.”

Altimmune has no internal manufacturing and expects to rely on third-party manufacturers for clinical and any future commercial supply of its candidates; those manufacturers must clear FDA inspection, creating supply and compliance dependency.

“We expect to rely on third parties for the manufacture of clinical and, if approved for marketing, commercial quantities of our product candidates.”